Medigene, bluebird bio Expand Cancer Immunotherapy Collaboration – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
Medigene, bluebird bio Expand Cancer Immunotherapy Collaboration
Genetic Engineering & Biotechnology News Medigene has agreed to expand its nearly two-year-old, up-to-$1 billion-plus cancer immunotherapy collaboration with bluebird bio, saying today that the expansion could generate up to $509 million-plus more for Medigene, nearly all of that tied to … Bluebird bio dives deeper into its TCR alliance with Medigene, adding $500M in milestones and 2 new targets German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn |
